Table 2.
Summary of treatments
| Items | TOCE | TOCE + HAIC | Provability 95%CI |
|
|---|---|---|---|---|
| n = 9 | n = 10 | |||
| Number of Treatment Session | (1/2/3/4/5/6/7/8) | 6/1/1/1/0/0/0/0 | 3/1/1/1/2/1/0/1 | 0.057 |
| Total | 15 | 36 | ||
| Median | 1 | 3.5 | ||
| Range | 1–4 | 1–8 | ||
| Interval between Sessions (day) | Median | 94.5 | 90.5 | 0.96 |
| Range | 56–259 | 48–518 | ||
| DDP-H (mg/body) | Median | N/A | 80 | N/A |
| Range | N/A | 40–100 | ||
| Miriplatin (mg/body) | Median | 62 | 62 | 0.99 |
| Range | 40–120 | 16–120 | ||
| anti-tumor Effecta | CR | 0 (0) | 6 (3) | 0.0025 |
| PR | 0 (0) | 7 (2) | ||
| SD | 6 (3) | 15 (5) | ||
| PD | 9 (9) | 8 (8) | ||
| Not evaluable | 0 | 0 | ||
| DCR (%) | 40.0 | 77.8 | ||
| Disease Progression (day) | Median | 91 | 423 | 0.025 |
| Range | 29–322 | 34–1243 | 1.17–10.86 | |
| Overall Survival (day) | Median | 706 | 733 | 0.40 |
| Range | 62–1176 | 384–1827 | 0.54–4.54 |
a anti-tumor effect was evaluated based on the modified Response Evaluation Criteria In Solid Tumors guideline. CR complete response, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate, HR hazard ratio, TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy